Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ping Chi

Showing results (221-230 of 264) with videos related to

Pageof 27
Sort By:
Cancer Discovery|November 23, 2017
FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal TumorLeili Ran, Yuedan Chen, Jessica Sher, et al.
Cancer Research Communications|June 11, 2026
Predicting clinical sensitivities of PDGFRA exon 18 mutations to imatinib and avapritinib to optimize gastrointestinal stromal tumor treatmentHomma M Khosroyani, Alina Teuber, Ajia Town, et al.
Nature Genetics|September 22, 2014
PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumorsWilliam Lee, Sewit Teckie, Thomas Wiesner, et al.
Angewandte Chemie (International Ed. in English)|January 13, 2021
An Efficient Turing-Type Ag<sub>2</sub> Se-CoSe<sub>2</sub> Multi-Interfacial Oxygen-Evolving Electrocatalyst*Xiao-Long Zhang, Peng-Peng Yang, Ya-Rong Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2016
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus IpilimumabSandra P D'Angelo, Alexander N Shoushtari, Mary Louise Keohan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced SarcomaMrinal M Gounder, Evan Rosenbaum, Nian Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced SarcomaNicholas D Klemen, Sinchun Hwang, Martina Bradic, et al.
Journal for Immunotherapy of Cancer|April 2, 2022
Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single centerEvan Rosenbaum, Cristina R Antonescu, Shaleigh Smith, et al.
Journal for Immunotherapy of Cancer|September 5, 2025
High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapyBenjamin A Nacev, Martina Bradic, Hyung Jun Woo, et al.
Cancer Cell|November 21, 2017
Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration ResistanceShipra Shukla, Joanna Cyrta, Devan A Murphy, et al.
Pageof 27

Showing results (221-230 of 264) with videos related to

Sort By:
Pageof 27
Cancer Discovery|November 23, 2017
FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal TumorLeili Ran, Yuedan Chen, Jessica Sher, et al.
Cancer Research Communications|June 11, 2026
Predicting clinical sensitivities of PDGFRA exon 18 mutations to imatinib and avapritinib to optimize gastrointestinal stromal tumor treatmentHomma M Khosroyani, Alina Teuber, Ajia Town, et al.
Nature Genetics|September 22, 2014
PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumorsWilliam Lee, Sewit Teckie, Thomas Wiesner, et al.
Angewandte Chemie (International Ed. in English)|January 13, 2021
An Efficient Turing-Type Ag<sub>2</sub> Se-CoSe<sub>2</sub> Multi-Interfacial Oxygen-Evolving Electrocatalyst*Xiao-Long Zhang, Peng-Peng Yang, Ya-Rong Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2016
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus IpilimumabSandra P D'Angelo, Alexander N Shoushtari, Mary Louise Keohan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced SarcomaMrinal M Gounder, Evan Rosenbaum, Nian Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced SarcomaNicholas D Klemen, Sinchun Hwang, Martina Bradic, et al.
Journal for Immunotherapy of Cancer|April 2, 2022
Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single centerEvan Rosenbaum, Cristina R Antonescu, Shaleigh Smith, et al.
Journal for Immunotherapy of Cancer|September 5, 2025
High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapyBenjamin A Nacev, Martina Bradic, Hyung Jun Woo, et al.
Cancer Cell|November 21, 2017
Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration ResistanceShipra Shukla, Joanna Cyrta, Devan A Murphy, et al.
Pageof 27